This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone
by Zacks Equity Research
Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.
Illumina (ILMN) to Enable Tertiary Analysis With New Launch
by Zacks Equity Research
Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.
Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Illumina (ILMN) Unveils Complete Long Reads Technology
by Zacks Equity Research
Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.
Company News for Mar 14, 2023
by Zacks Equity Research
Companies In The News Are: SGEN, PFE, PODD, SIVB, ILMN, PNC.
Steer Clear Of These 4 Toxic Stocks to Avoid Losses
by Rimmi Singhi
Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.
Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access
by Zacks Equity Research
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.
Illumina (ILMN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Illumina (ILMN) Misses Q4 Earnings Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of -26.32% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.
These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio
by Rimmi Singhi
Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.
Illumina (ILMN), Nashville Biosciences Partner With Amgen
by Zacks Equity Research
Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.
New Strong Sell Stocks for January 4th
by Zacks Equity Research
AVAH, CBRL and ILMN have been added to the Zacks Rank #5 (Strong Sell) List on January 4, 2023.
5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio
by Rimmi Singhi
Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.
Are Options Traders Betting on a Big Move in Illumina (ILMN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Illumina (ILMN) Q3 Earnings Beat Estimates, '22 View Slashed
by Zacks Equity Research
Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).
Illumina (ILMN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 17.24% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Illumina (ILMN) Ahead of Earnings?
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Clene Inc. (CLNN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Clene Inc. (CLNN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Illumina (ILMN) in Q3 Earnings?
by Zacks Equity Research
The extended lockdown issues in limited geographies, including Greater China, where Illumina (ILMN) has extensive business, are expected to have adversely impacted its top line during the third quarter.